Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ/Ⅱ Study
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
• Consistent with the diagnosis of AML
• Age≥18 years at time of consent
• KPS(Karnofsky Performance Scale) ≥70
• Patient's written informed consent
• No steroid therapy within 4 weeks of first DC vaccination
• Stable disease, complete response and partial response(WHO, RECIST)
• Predicted survival≥3 months